In Vivo Assays for Amyloid-Related Diseases.

Annu Rev Anal Chem (Palo Alto Calif)

1Department of Pharmacy and Pharmaceutical Technology and Department of Physical Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain; email:

Published: July 2024

AI Article Synopsis

  • Amyloid-related diseases like Alzheimer's and Parkinson's are caused by harmful protein aggregates called amyloid fibrils.
  • Standard analytical methods are crucial for studying these diseases, offering insights into amyloid formation, drug behaviors, and overall disease mechanisms.
  • Despite ethical concerns, animal models are key in research, and this review aims to categorize the main analytical methods used in these models to improve understanding and treatment of amyloid-related conditions.

Article Abstract

Amyloid-related diseases, such as Alzheimer's and Parkinson's disease, are devastating conditions caused by the accumulation of abnormal protein aggregates known as amyloid fibrils. While assays involving animal models are essential for understanding the pathogenesis and developing therapies, a wide array of standard analytical techniques exists to enhance our understanding of these disorders. These techniques provide valuable information on the formation and propagation of amyloid fibrils, as well as the pharmacokinetics and pharmacodynamics of candidate drugs. Despite ethical concerns surrounding animal use, animal models remain vital tools in the search for treatments. Regardless of the specific animal model chosen, the analytical methods used are usually standardized. Therefore, the main objective of this review is to categorize and outline the primary analytical methods used in in vivo assays for amyloid-related diseases, highlighting their critical role in furthering our understanding of these disorders and developing effective therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-anchem-061622-023326DOI Listing

Publication Analysis

Top Keywords

amyloid-related diseases
12
vivo assays
8
assays amyloid-related
8
amyloid fibrils
8
animal models
8
understanding disorders
8
analytical methods
8
diseases amyloid-related
4
diseases alzheimer's
4
alzheimer's parkinson's
4

Similar Publications

Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease pathologically characterized by the progressive accumulation of amyloid-beta (Aβ) peptide in cerebrovascular walls, affecting both cortical and leptomeningeal vessels. Amyloid deposition results in fragile vessels, which may lead to lobar intracerebral hemorrhage (ICH) and cognitive impairment. To evaluate the probability and severity of CAA, the imaging markers depicted on CT and MRI techniques are crucial, as brain pathological examination is highly invasive.

View Article and Find Full Text PDF

Background: Aducanumab, a monoclonal antibody, received approval for the treatment of Alzheimer's disease in 2021. However, it remains controversial over the security of this drug. In this study, aducanumab-related adverse events (AEs) were evaluated through data mining based on the FDA Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Alzheimer's disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions. The central and early role of β-amyloid in the pathogenesis of Alzheimer's disease is supported by a plethora of studies including genetic analyses, biomarker research and genome-wide association studies in both familial (early-onset) and sporadic (late-onset) forms of Alzheimer's. Monoclonal antibodies directed against β-amyloid demonstrate slowing of the clinical deterioration of patients with early Alzheimer's disease.

View Article and Find Full Text PDF

Objective: Report a case of an apolipoprotein E (APOE)ε2 carrier receiving lecanemab who developed late onset intracerebral hemorrhage (ICH) following amyloid-related imaging abnormalities-hemorrhage (ARIA-H).

Method: We detail the history and neuroimaging findings of a 73-year-old male with Alzheimer's disease (APOEε2/ε3 status) who developed ICH after mild ARIA-H and suffering a fall.

Results: The patient developed mild ARIA-H after his 13th infusion that was proceeded by left temporo-occipital hemorrhage following his 14th infusion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!